§ 02 — Comparison

Compare regulatory pathways side-by-side

Benchmark MAHMAH, GMPGMP, HTAHTA and pathway requirements across up to three markets.

Country A

Country B

Country C

Highlight differences

Criterion	🇭🇰Hong Kong	🇺🇸United States
Authority & dossier
Regulatory authority	DH DO	FDA
English submissions	Yes	Yes
CTD accepted	Yes	Yes
eCTD accepted	No	Yes
Reliance pathway	Available	None
Reference agencies	FDA (US), EMA, MHRA (UK), PMDA (Japan) +6	—
Lead pathway (timeline & fees) — Registration of Pharmaceutical Products containing NCE/NBE — '1+' Mechanism · New Drug Application — 505(b)(1)
Pathway name	Registration of Pharmaceutical Products containing NCE/NBE — '1+' Mechanism	New Drug Application — 505(b)(1)
Approval timeline	270–540 days	304–365 days
Application fee	HKD 12,330	USD 4,310,002
Annual renewal	HKD 1,135	USD 416,734
Local representative	Required	Not required
Local manufacturing	Not required	Not required
GMP inspection	Required	Required
MAH & local presence
Local entity required	Yes	No
Local responsible person	Yes	Yes
RP role	Certificate holders must designate a registered pharmacist (under the Pharmacists Registration Ordinance) as the responsible person for the licensed premises, and a contact for pharmacovigilance reporting to the Drug Office.	US Agent: a person residing or maintaining a place of business in the US, designated to act on behalf of the foreign establishment for FDA communications, including notification of inspections.
Accelerated pathways
Designations available	1 designation	6 designations
Examples	'1+' Mechanism (Reliance with reduced CPP requirement)	Priority Review, Breakthrough Therapy Designation, Accelerated Approval — Subpart H/E +3
Post-approval lifecycle
Variations framework	Variations classified per Drug Office guidelines into changes requiring approval (e.g. new indications, formulation, manufacturing site) and notifications (administrative). New indications under '1+' follow the new-drug pathway.	FDA classifies post-approval changes as: Annual Reportable, Changes Being Effected (CBE-0 immediate, CBE-30 with 30-day pre-implementation notice), and Prior Approval Supplements (PAS) — the most significant changes requiring FDA approval before implementation. Major manufacturing or labelling changes typically require a PAS.
Renewal cycle	Certificate of Registration is valid for 5 years and must be renewed before expiry. Renewal requires up-to-date CMC, safety and labelling information, plus retention fee.	FDA does not require periodic renewal of NDAs or BLAs — approvals remain in effect indefinitely subject to compliance, payment of annual program fees, and post-marketing requirements. Annual reports are required.
Pharmacovigilance	Certificate holders must report serious adverse drug reactions to the Drug Office's pharmacovigilance unit within statutory timelines, submit PSURs aligned to ICH E2C(R2), and maintain an RMP for new active substances. The Drug Office issues safety alerts via the Drug Office website.	Mandatory expedited reporting of serious unexpected ADRs within 15 calendar days; periodic safety reports (PADERs/PAERs) for the first 3 years post-approval, then annually. PSURs in ICH E2C(R2) format accepted in lieu of PADERs by agreement. FAERS database receives spontaneous reports. Post-Marketing Requirements (PMRs) and Commitments (PMCs) tracked publicly.
Unlicensed access
Named Patient Supply	Available	Available
Compassionate Use	Available	Available
Emergency Import	Available	Available
Parallel Import	Permitted	Not permitted
Clinical trials
CTA approval	Required	Required
Ethics approval	Yes	Yes
CTA timeline	30–90 days	30–30 days
GCP standard	ICH E6(R2/R3) GCP; Drug Office Good Clinical Practice Guidelines	ICH E6(R3) (adopted via FDA guidance January 2025); 21 CFR 312, 314, 50, 56
Pricing & reimbursement
Price regulation	Free pricing	Free pricing
Reference pricing	No	No
HTA required	Yes	No
HTA body	Hospital Authority — Drug Advisory Committee (DAC) and Drug Utilisation Review Committee (DUC) for HA Drug Formulary listing	ICER (Institute for Clinical and Economic Review) — independent, non-binding

Verdict colours indicate lower, moderate, or higher regulatory burden — they're not value judgements on a market.

Authority & dossier

Regulatory authority

Hong KongDH DO
United StatesFDA

English submissions

Hong KongYes
United StatesYes

CTD accepted

Hong KongYes
United StatesYes

eCTD accepted

Hong KongNo
United StatesYes

Reliance pathway

Hong KongAvailable
United StatesNone

Reference agencies

Hong KongFDA (US), EMA, MHRA (UK), PMDA (Japan) +6
United States—

Lead pathway (timeline & fees) — Registration of Pharmaceutical Products containing NCE/NBE — '1+' Mechanism · New Drug Application — 505(b)(1)

Pathway name

Hong KongRegistration of Pharmaceutical Products containing NCE/NBE — '1+' Mechanism
United StatesNew Drug Application — 505(b)(1)

Approval timeline

Hong Kong270–540 days
United States304–365 days

Application fee

Hong KongHKD 12,330
United StatesUSD 4,310,002

Annual renewal

Hong KongHKD 1,135
United StatesUSD 416,734

Local representative

Hong KongRequired
United StatesNot required

Local manufacturing

Hong KongNot required
United StatesNot required

GMP inspection

Hong KongRequired
United StatesRequired

MAH & local presence

Local entity required

Hong KongYes
United StatesNo

Local responsible person

Hong KongYes
United StatesYes

RP role

Hong KongCertificate holders must designate a registered pharmacist (under the Pharmacists Registration Ordinance) as the responsible person for the licensed premises, and a contact for pharmacovigilance reporting to the Drug Office.
United StatesUS Agent: a person residing or maintaining a place of business in the US, designated to act on behalf of the foreign establishment for FDA communications, including notification of inspections.

Accelerated pathways

Designations available

Hong Kong1 designation
United States6 designations

Examples

Hong Kong'1+' Mechanism (Reliance with reduced CPP requirement)
United StatesPriority Review, Breakthrough Therapy Designation, Accelerated Approval — Subpart H/E +3

Post-approval lifecycle

Variations framework

Hong KongVariations classified per Drug Office guidelines into changes requiring approval (e.g. new indications, formulation, manufacturing site) and notifications (administrative). New indications under '1+' follow the new-drug pathway.
United StatesFDA classifies post-approval changes as: Annual Reportable, Changes Being Effected (CBE-0 immediate, CBE-30 with 30-day pre-implementation notice), and Prior Approval Supplements (PAS) — the most significant changes requiring FDA approval before implementation. Major manufacturing or labelling changes typically require a PAS.

Renewal cycle

Hong KongCertificate of Registration is valid for 5 years and must be renewed before expiry. Renewal requires up-to-date CMC, safety and labelling information, plus retention fee.
United StatesFDA does not require periodic renewal of NDAs or BLAs — approvals remain in effect indefinitely subject to compliance, payment of annual program fees, and post-marketing requirements. Annual reports are required.

Pharmacovigilance

Hong KongCertificate holders must report serious adverse drug reactions to the Drug Office's pharmacovigilance unit within statutory timelines, submit PSURs aligned to ICH E2C(R2), and maintain an RMP for new active substances. The Drug Office issues safety alerts via the Drug Office website.
United StatesMandatory expedited reporting of serious unexpected ADRs within 15 calendar days; periodic safety reports (PADERs/PAERs) for the first 3 years post-approval, then annually. PSURs in ICH E2C(R2) format accepted in lieu of PADERs by agreement. FAERS database receives spontaneous reports. Post-Marketing Requirements (PMRs) and Commitments (PMCs) tracked publicly.

Unlicensed access

Named Patient Supply

Hong KongAvailable
United StatesAvailable

Compassionate Use

Hong KongAvailable
United StatesAvailable

Emergency Import

Hong KongAvailable
United StatesAvailable

Parallel Import

Hong KongPermitted
United StatesNot permitted

Clinical trials

CTA approval

Hong KongRequired
United StatesRequired

Ethics approval

Hong KongYes
United StatesYes

CTA timeline

Hong Kong30–90 days
United States30–30 days

GCP standard

Hong KongICH E6(R2/R3) GCP; Drug Office Good Clinical Practice Guidelines
United StatesICH E6(R3) (adopted via FDA guidance January 2025); 21 CFR 312, 314, 50, 56

Pricing & reimbursement

Price regulation

Hong KongFree pricing
United StatesFree pricing

Reference pricing

Hong KongNo
United StatesNo

HTA required

Hong KongYes
United StatesNo

HTA body

Hong KongHospital Authority — Drug Advisory Committee (DAC) and Drug Utilisation Review Committee (DUC) for HA Drug Formulary listing
United StatesICER (Institute for Clinical and Economic Review) — independent, non-binding